Lucence, A*STAR Share Study Data Showing SAFER™ Sample Saliva Collection Kit for COVID-19 Inactivates Collected Virus
- SAFER™ Sample Kit offers accessible, non-invasive, and safe sample collection via saliva to enable cost-effective mass testing; Proprietary reagent inactivates virus in sample, while keeping sample stable at room temperature for up to one week
Singapore, 16 June 2020 – Molecular diagnostics company Lucence and the Agency for Science, Technology and Research (A*STAR) today announced study results indicating that the reagent used in Lucence’s SAFER Sample saliva collection kit inactivates
SARS-CoV-2 within 45 seconds of sample collection. This proprietary reagent also stabilizes viral RNA at room temperature for up to one week. Together, these properties enable accessible, non-invasive, and safe sample collection via saliva,
which is critical to scaling cost-effective testing worldwide. The reagent used in Lucence’s SAFER Sample kit was invented at A*STAR’s Institute of Bioengineering and Nanotechnology.
The SAFER Sample Collection Kit is registered as a Class A medical device with the Health Sciences Authority of Singapore and is an easy-to-use saliva collection kit that comes with a bottle of stabilization fluid to be mixed with the sample at the point
of collection, keeping viral RNA stable at room temperature for up to one week. While conventional viral transport media requires cold-chain transport to prevent sample degradation, which can drive up associated costs and limit testing geography,
SAFER Sample’s proprietary media means samples can be transported to a lab without the need for chilling.
In this new study, Lucence and A*STAR demonstrated that the proprietary reagent provided with the SAFER Sample kit also achieved complete inactivation of SARS-CoV-2 virus within 45 seconds of exposure. Conventional viral transport media used for collecting
nasal and nasopharyngeal swab specimens do not inactivate viral samples, creating risk of exposure to active virus during transportation from collection sites to the laboratory and higher costs associated with biohazard handling procedures.
SAFER Sample kit's viral inactivation capabilities could mean enhanced safety and reduced risk of exposure for any individual involved in the collection, transport, and testing processes. Lucence worked with the Diagnostics Development (DxD)
Hub of A*STAR to evaluate the virucidal properties of the SAFER Sample reagent. Duke-NUS Medical School was also engaged to perform the virucidal work with SARS-CoV-2 virus.
Mass testing is key to safely testing and screening large populations to reduce the risk of COVID-19 transmission, morbidity and mortality. By eliminating obstacles to sample integrity and, now, biosafety through viral inactivation, the SAFER Sample
kit could expand testing geography, decrease associated costs, and increase efficiency of testing at scale compared to approaches utilizing conventional viral transport media.
Studies with clinical partners are ongoing to further evaluate the performance of the SAFER Sample kit. With the support of DxD Hub in verification and validation, quality management system (QMS), and regulatory registration, Lucence has received ISO13485:2016
certification for its QMS which controls the processes for the manufacture of the SAFER Sample Saliva Specimen Collection Kit.
For media queries and clarifications, please contact:
Mr Gabriel Yap
Ms Lynn Hong
Tel: +65 6419 6597
Lucence is a precision oncology company that makes state-of-the-art, highly sensitive liquid biopsy tests for disease detection and treatment selection. Lucence is headquartered in Palo Alto and Singapore, and its services are delivered
worldwide through an accredited central laboratory. Visit www.lucence.com
for more information.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation- we collaborate with
our partners in both the public and private sectors to benefit society.
As a Science and Technology Organisation- A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore- and enhances lives by contributing to societal benefits such as improving outcomes in healthcare-
urban living- and sustainability.
We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and Research Institutes- the wider research community and industry. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities
primarily located in Biopolis and Fusionopolis.
For ongoing news, visit www.a-star.edu.sg. For information on the Diagnostics Development
(DxD) Hub, visit https://www.a-star.edu.sg/accelerate/innovation-offerings/diagnostics-development-hub